New Life Science VC Launches With €210m Fund

Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its 'asset-centric' approach to investing. The new firm launches with the close of Medicxi Ventures 1 (MV1), a new €210m ($250m) fund that will continue focusing on asset-centric, early-stage investments in European life science programs.

Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its 'asset-centric' approach to investing. The new firm launches with the close of Medicxi Ventures 1 (MV1), a new €210m ($250m) fund that will continue focusing on asset-centric, early-stage investments in European life science programs.

Medicxi Ventures will be managed by four general partners: Francesco De Rubertis, David Grainger, Kevin Johnson and Michèle Ollier. The...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip